Event Recap: Leveraging FDA Experience to Shape Future Strategy

The FDA environment is moving quickly. Leadership transitions, enforcement signals, staffing pressure, state activity, and new technology all affect how companies prepare for compliance.

In the second session of Gardner Law's 10-year anniversary program, Nathan Downing, Rebecca Zadaka, Brynn Stanley, and Darya Lucas discussed how FDA-regulated companies can use past FDA experience to shape future strategy. The discussion addressed agency priorities, quality system expectations, clinical trial oversight, cybersecurity, AI-enabled products, and the need to connect regulatory planning with reimbursement and commercialization.

FDA Signals Need Active Monitoring

The regulatory team began by placing FDA strategy in a practical operating context. Product development, clinical planning, submissions, and post-market obligations often unfold over years, while FDA priorities can shift more quickly through leadership changes, reviewer bandwidth, enforcement initiatives, and center-level focus areas.

For FDA-regulated companies, that means regulatory strategy should account for more than the text of current requirements. Companies should monitor where FDA is directing attention, how the agency is communicating risk, and which issues are drawing enforcement interest. That awareness can help shape submission strategy, reporting decisions, advertising review, clinical trial compliance, and post-market planning.

“What FDA focuses on is what you should focus on, especially from an enforcement standpoint.”
Nathan Downing, Managing Attorney

That point has practical consequences. Prior agency practice may help frame the next interaction, though companies should recalibrate their approach to the current reviewer, center, policy environment, and record.

FDA Scrutiny Beyond Submissions

The panel’s discussion of advertising, clinical trials, and state activity pointed to a broader regulatory reality: FDA strategy cannot be limited to premarket submissions or formal agency meetings. Companies also need to monitor how products are promoted, how clinical responsibilities are managed, and how state-level requirements may affect distribution or commercialization.

That point was especially clear in the discussion of GLP-1 products. Rebecca Zadaka explained that FDA is watching how companies distinguish between FDA-approved drugs and compounded versions, particularly where comparative claims or product descriptions may cause consumers to misunderstand the status, testing, or approval of the product. 

“FDA is very much aware of what is going on with GLP-1s and is looking at messaging that may mislead consumers about compounded products and FDA-approved drugs.”
Rebecca Zadaka, Associate Attorney

The same requisite discipline applies outside advertising review. Clinical trial sponsors remain responsible for oversight of Contract Research Organizations, adverse event reporting, and risk-based decision-making, even when key activities are outsourced. State licensing changes and “It Has Come to Our Attention” letters can also create meaningful response burdens before a company receives a more formal enforcement communication. 

The practical takeaway is that regulatory strategy should track where the company actually touches the market. Claims, contractors, reporting systems, licenses, and agency correspondence all need enough internal ownership to identify risk early and respond before the issue becomes harder to manage.

Innovation Programs Require Early Planning

The panel also recognized that FDA programs intended to spur innovation can create opportunities for earlier engagement, more structured interaction, and faster development pathways. Those opportunities have the most value when companies identify them early enough to build them into regulatory, clinical, and reimbursement strategy.

A faster path to market has limited value if customers cannot obtain payment for the technology once it is available. The panel emphasized that regulatory strategy and reimbursement strategy should be developed together, especially for medical technologies with novel claims or care pathways.

QMSR, Cybersecurity, and AI Need Lifecycle Thinking

For medical device companies, the move from the Quality System Regulation to the Quality Management System Regulation remains a major transition. Companies with experience under the old QSR and ISO 13485 may be able to leverage that experience. QMSR readiness still requires meaningful work on risk management, CAPA, supplier oversight, post-market surveillance, and inspection response.

“FDA continues to emphasize that sponsors need to take responsibility for contractors and make risk-based decisions in clinical trials.”
Brynn Stanley, Associate Attorney

The panel also discussed AI-enabled products and cybersecurity. AI-enabled devices raise lifecycle questions because performance can evolve over time. Cybersecurity is increasingly tied to safety and effectiveness for connected devices, particularly where an issue could affect device function or patient safety.

“Cybersecurity is becoming part of the safety and effectiveness of a device. FDA wants to know, in real terms, what risks you see and how you will mitigate them.”
Darya Lucas, Associate Attorney

Practical Takeaways

• Monitor FDA leadership, center-level priorities, and agency communications because policy signals can shift quickly.
• Build QMSR readiness around risk management, CAPA, post-market surveillance, supplier oversight, and inspection response.
• Treat AI-enabled devices as lifecycle products that require ongoing monitoring, validation, and performance oversight.
• Address cybersecurity early in product design and submission planning.
• Develop regulatory strategy with reimbursement, clinical, quality, and commercial planning in view.

Watch the Discussion and Contact Gardner Law

Watch the session recording above and download the slides for more detail. If your organization is evaluating FDA regulatory strategy, QMSR readiness, clinical trial oversight, cybersecurity expectations, AI-enabled products, or agency engagement, contact Gardner Law for assistance planning, documenting, and pressure-testing your approach before FDA questions, submission timing, or inspection activity force the issue.